248 related articles for article (PubMed ID: 32593209)
1. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
Koschmieder S; Jost E; Cornelissen C; Müller T; Schulze-Hagen M; Bickenbach J; Marx G; Kleines M; Marx N; Brümmendorf TH; Dreher M
Eur J Haematol; 2020 Nov; 105(5):655-658. PubMed ID: 32593209
[TBL] [Abstract][Full Text] [Related]
2. The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Neubauer A; Johow J; Mack E; Burchert A; Meyn D; Kadlubiec A; Torje I; Wulf H; Vogelmeier CF; Hoyer J; Skevaki C; Muellenbach RM; Keller C; Schade-Brittinger C; Rolfes C; Wiesmann T
Leukemia; 2021 Oct; 35(10):2917-2923. PubMed ID: 34385593
[TBL] [Abstract][Full Text] [Related]
3. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Goker Bagca B; Biray Avci C
Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
Cao Y; Wei J; Zou L; Jiang T; Wang G; Chen L; Huang L; Meng F; Huang L; Wang N; Zhou X; Luo H; Mao Z; Chen X; Xie J; Liu J; Cheng H; Zhao J; Huang G; Wang W; Zhou J
J Allergy Clin Immunol; 2020 Jul; 146(1):137-146.e3. PubMed ID: 32470486
[TBL] [Abstract][Full Text] [Related]
5. Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.
Mortara A; Mazzetti S; Margonato D; Delfino P; Bersano C; Catagnano F; Lauriola M; Grosso P; Perseghin G; Ippoliti G
Clin Transl Sci; 2021 May; 14(3):1062-1068. PubMed ID: 33403775
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
7. Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study.
Vannucchi AM; Sordi B; Morettini A; Nozzoli C; Poggesi L; Pieralli F; Bartoloni A; Atanasio A; Miselli F; Paoli C; Loscocco GG; Fanelli A; Para O; Berni A; Tassinari I; Zammarchi L; Maggi L; Mazzoni A; Scotti V; Falchetti G; Malandrino D; Luise F; Millotti G; Bencini S; Capone M; Piccinni MP; Annunziato F; Guglielmelli P;
Leukemia; 2021 Apr; 35(4):1121-1133. PubMed ID: 32814839
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids.
Sarmiento M; Rojas P; Jerez J; Bertín P; Campbell J; García MJ; Pereira J; Triantafilo N; Ocqueteau M
Acta Haematol; 2021; 144(6):620-626. PubMed ID: 34111867
[TBL] [Abstract][Full Text] [Related]
9. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
Caocci G; La Nasa G
Ann Hematol; 2020 Jul; 99(7):1675-1676. PubMed ID: 32405693
[No Abstract] [Full Text] [Related]
10. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
Chen CX; Wang JJ; Li H; Yuan LT; Gale RP; Liang Y
Leukemia; 2021 Sep; 35(9):2616-2620. PubMed ID: 33990684
[TBL] [Abstract][Full Text] [Related]
11. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
13. Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
Maffioli M; Giorgino T; Mora B; Iurlo A; Elli E; Finazzi MC; Caramella M; Rumi E; Carraro MC; Polverelli N; D'Adda M; Malato S; Rossi M; Molteni A; Vismara A; Sissa C; Spina F; Anghilieri M; Cattaneo D; Renso R; Bellini M; Pioltelli ML; Cavalloni C; Barraco D; Accetta R; Bertù L; Della Porta MG; Passamonti F
Blood Adv; 2019 Nov; 3(21):3196-3200. PubMed ID: 31698448
[TBL] [Abstract][Full Text] [Related]
14. Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.
Beauverd Y; Samii K
Int J Hematol; 2014 Nov; 100(5):498-501. PubMed ID: 25034748
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib for the Treatment of Portal Hypertension in a Patient With Primary Myelofibrosis.
Tan HK; Leow WQ; Chang PE
Gastroenterology; 2019 Nov; 157(5):e26-e27. PubMed ID: 28478151
[No Abstract] [Full Text] [Related]
16. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Neubauer A; Wiesmann T; Vogelmeier CF; Mack E; Skevaki C; Gaik C; Keller C; Figiel J; Sohlbach K; Rolfes C; Renz H; Wulf H; Burchert A
Leukemia; 2020 Aug; 34(8):2276-2278. PubMed ID: 32555296
[No Abstract] [Full Text] [Related]
18. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
19. Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
Del Rosario M; Tsai H; Dasanu CA
J Oncol Pharm Pract; 2018 Apr; 24(3):226-228. PubMed ID: 28436280
[TBL] [Abstract][Full Text] [Related]
20. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
